ArticleAmerican journal of translational research2024
Clinical efficacy of dexmedetomidine preemptive analgesia in breast tumor resection.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy of dexmedetomidine preemptive analgesia in patients undergoing mastectomy.
methodsA retrospective study was conducted, including 236 patients who underwent breast tumor resection. Of these, 131 patients in the control group received routine postoperative intravenous patient-controlled analgesia, while 105 patients in the preemptive analgesia group received dexmedetomidine preemptive analgesia during surgery. Visual analog scale (VAS) scores, Ramsay sedation scores, clinical efficacy, pain mediator levels, renal function indices, immune function indices, and adverse effects were statistically analyzed.
resultsThe preemptive analgesia group had lower VAS scores and Ramsay scores postoperatively (both P < 0.05). The success rate of analgesia was significantly higher in the preemptive analgesia group compared to the control group (84.8% vs. 74.0%, P < 0.05). After surgery, the levels of pain mediators, including prostaglandin E2 (PGE2), substance P (SP), and neuropeptide Y (NPY), initially increased and then decreased, with lower levels observed in the preemptive analgesia group (all P < 0.05). Renal function indices, including creatinine (Cr), blood urea nitrogen (BUN), and neutrophil gelatinase-associated lipocalin (NGAL), showed a similar trend, with lower levels in the preemptive analgesia group (all P < 0.05). Immune function markers, such as CD3+, CD4+, CD8+, and CD4/CD8+ ratios, demonstrated smaller changes in the preemptive analgesia group compared to the control group (all P < 0.05). The total adverse reaction rate was lower in the preemptive analgesia group (P < 0.05).
conclusionDexmedetomidine preemptive analgesia demonstrates significant clinical benefits in patients undergoing breast tumor resection, including better analgesic efficacy, reduced pain mediator and renal function index levels, improved immune function preservation, and fewer adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.